1. Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2
- Author
-
Salwa Naushin, Viren Sardana, Rajat Ujjainiya, Nitin Bhatheja, Rintu Kutum, Akash Kumar Bhaskar, Shalini Pradhan, Satyartha Prakash, Raju Khan, Birendra Singh Rawat, Karthik Bharadwaj Tallapaka, Mahesh Anumalla, Giriraj Ratan Chandak, Amit Lahiri, Susanta Kar, Shrikant Ramesh Mulay, Madhav Nilakanth Mugale, Mrigank Srivastava, Shaziya Khan, Anjali Srivastava, Bhawana Tomar, Murugan Veerapandian, Ganesh Venkatachalam, Selvamani Raja Vijayakumar, Ajay Agarwal, Dinesh Gupta, Prakash M Halami, Muthukumar Serva Peddha, Gopinath M Sundaram, Ravindra P Veeranna, Anirban Pal, Vinay Kumar Agarwal, Anil Ku Maurya, Ranvijay Kumar Singh, Ashok Kumar Raman, Suresh Kumar Anandasadagopan, Parimala Karuppanan, Subramanian Venkatesan, Harish Kumar Sardana, Anamika Kothari, Rishabh Jain, Anupama Thakur, Devendra Singh Parihar, Anas Saifi, Jasleen Kaur, Virendra Kumar, Avinash Mishra, Iranna Gogeri, Geethavani Rayasam, Praveen Singh, Rahul Chakraborty, Gaura Chaturvedi, Pinreddy Karunakar, Rohit Yadav, Sunanda Singhmar, Dayanidhi Singh, Sharmistha Sarkar, Purbasha Bhattacharya, Sundaram Acharya, Vandana Singh, Shweta Verma, Drishti Soni, Surabhi Seth, Sakshi Vashisht, Sarita Thakran, Firdaus Fatima, Akash Pratap Singh, Akanksha Sharma, Babita Sharma, Manikandan Subramanian, Yogendra S Padwad, Vipin Hallan, Vikram Patial, Damanpreet Singh, Narendra Vijay Tripude, Partha Chakrabarti, Sujay Krishna Maity, Dipyaman Ganguly, Jit Sarkar, Sistla Ramakrishna, Balthu Narender Kumar, Kiran A Kumar, Sumit G Gandhi, Piyush Singh Jamwal, Rekha Chouhan, Vijay Lakshmi Jamwal, Nitika Kapoor, Debashish Ghosh, Ghanshyam Thakkar, Umakanta Subudhi, Pradip Sen, Saumya Ray Chaudhury, Rashmi Kumar, Pawan Gupta, Amit Tuli, Deepak Sharma, Rajesh P Ringe, Amarnarayan D, Mahesh Kulkarni, Dhansekaran Shanmugam, Mahesh S Dharne, Sayed G Dastager, Rakesh Joshi, Amita P Patil, Sachin N Mahajan, Abujunaid Habib Khan, Vasudev Wagh, Rakesh Kumar Yadav, Ajinkya Khilari, Mayuri Bhadange, Arvindkumar H Chaurasiya, Shabda E Kulsange, Krishna Khairnar, Shilpa Paranjape, Jatin Kalita, Narahari G Sastry, Tridip Phukan, Prasenjit Manna, Wahengbam Romi, Pankaj Bharali, Dibyajyoti Ozah, Ravi Kumar Sahu, Elapavalooru VSSK Babu, Rajeev Sukumaran, Aiswarya R Nair, Prajeesh Kooloth Valappil, Anoop Puthiyamadam, Adarsh Velayudhanpillai, Kalpana Chodankar, Samir Damare, Yennapu Madhavi, Ved Varun Aggarwal, Sumit Dahiya, Anurag Agrawal, Debasis Dash, and Shantanu Sengupta
- Subjects
SARS-CoV2 ,antibody stability ,sero-prevalence ,neutralizing antibody ,Medicine ,Science ,Biology (General) ,QH301-705.5 - Abstract
To understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India) conducted a serosurvey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested positive for SARS-CoV2 anti-nucleocapsid (anti-NC) antibodies, 95% of which had surrogate neutralization activity. Three-fourth of these recalled no symptoms. Repeat serology tests at 3 (n = 607) and 6 (n = 175) months showed stable anti-NC antibodies but declining neutralization activity. Local seropositivity was higher in densely populated cities and was inversely correlated with a 30-day change in regional test positivity rates (TPRs). Regional seropositivity above 10% was associated with declining TPR. Personal factors associated with higher odds of seropositivity were high-exposure work (odds ratio, 95% confidence interval, p value: 2.23, 1.92–2.59,
- Published
- 2021
- Full Text
- View/download PDF